Novel Oral Anticoagulants for Acute Coronary Syndrome, Atrial Fibrillation, and Venous Thromboembolism in the EU5 | Physician & Payer Forum | EU5 | 2015
How Are Payer Policies and Physician Preferences Shaping the Prescribing Landscape?
The European oral anticoagulation market has undergone a dramatic expansion in the treatment armamentarium in recent years, with the emergence of the novel oral anticoagulants (NOACs) and their approval for use in a range of indications. While the NOACs offer certain clinical and dosing advantages over the traditional mainstays of oral anticoagulation—the vitamin K antagonists (VKAs)—their relatively high cost means that the increasingly cost-conscious European markets have sought to impose certain restrictions on the use of these agents.
Related Market Assessment Reports
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
